Treatment of Perianal Dermatitis Caused by Group B Streptococci

First-Line Treatment Options

For non-allergic patients, penicillin is the preferred agent due to its narrow spectrum of activity, administered as penicillin G 5 million units IV initially, then 2.5 million units IV every 4 hours for inpatient cases, as recommended by the Centers for Disease Control and Prevention (CDC) 1, 2
Complete the full prescribed duration of treatment to ensure complete eradication and prevent recurrence, according to the CDC 3

For patients with penicillin allergy who are not at high risk for anaphylaxis, cefazolin or cephalexin is the preferred alternative, as recommended by the CDC 4, 5
For patients at high risk for anaphylaxis, treatment options include Clindamycin 900 mg IV every 8 hours (or oral equivalent for outpatients), but only if the isolate is confirmed susceptible, as recommended by the CDC 4, 5
Vancomycin 1 g IV every 12 hours is an option for patients with severe infection or when susceptibility results are unavailable, as recommended by the CDC 4, 5

Susceptibility testing should be performed on GBS isolates from penicillin-allergic patients at high risk for anaphylaxis, according to the CDC 5
Testing for inducible clindamycin resistance is necessary for isolates that are susceptible to clindamycin but resistant to erythromycin, as recommended by the CDC 4, 5
If an isolate is resistant to erythromycin, it might have inducible resistance to clindamycin even if it appears susceptible, according to the CDC 4

Underdosing or premature discontinuation of therapy may lead to treatment failure or recurrence, as noted by the Praxis Medical Insights 3
Failure to consider local resistance patterns when selecting empiric therapy could lead to treatment failure, according to the Praxis Medical Insights 3
No routine follow-up testing is required if symptoms resolve completely, as recommended by the Praxis Medical Insights 3